Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Intangibles (2018 - 2024)

Akebia Therapeutics (AKBA) has disclosed Intangibles for 7 consecutive years, with $9.0 million as the latest value for Q3 2024.

  • Quarterly Intangibles fell 80.0% to $9.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Sep 2024, down 80.0% year-over-year, with the annual reading at $36.0 million for FY2023, 50.0% down from the prior year.
  • Intangibles for Q3 2024 was $9.0 million at Akebia Therapeutics, down from $18.0 million in the prior quarter.
  • The five-year high for Intangibles was $282.1 million in Q1 2020, with the low at $9.0 million in Q3 2024.
  • Average Intangibles over 5 years is $95.6 million, with a median of $90.1 million recorded in 2022.
  • The sharpest move saw Intangibles fell 11.43% in 2020, then crashed 80.0% in 2024.
  • Over 5 years, Intangibles stood at $144.2 million in 2020, then decreased by 25.0% to $108.1 million in 2021, then crashed by 33.33% to $72.1 million in 2022, then tumbled by 50.0% to $36.0 million in 2023, then plummeted by 75.0% to $9.0 million in 2024.
  • According to Business Quant data, Intangibles over the past three periods came in at $9.0 million, $18.0 million, and $27.0 million for Q3 2024, Q2 2024, and Q1 2024 respectively.